# US 11,078,544 B2 · Method for identifying subjects with aggressive melanoma skin cancer at diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,544 B2
- Document ID: US11078544B2
- Status: Granted
- Kind: B2
- Application number: 16/289,897
- Filed: 2019-03-01
- Published: 2019-08-22
- Granted: 2021-08-03
- Earliest claimed: 2015-05-29
- Assignees: Universiteit Maastricht; Academisch Ziekenhuis Maastricht
- Applicants: Universiteit Maastricht; Academisch Ziekenhuis Maastricht
- Inventors: Manon Van Engeland; Leander Pieter Jo Van Neste; Karin Van Den Hurk
- Web page: https://patentgrep.com/patent/US11078544B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This disclosure is in the field of molecular biology and medical diagnosis and provides means and methods for determining the prognosis and disease outcome of a subject having a melanoma. More in particular, this disclosure provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.

## Claims

### Claim 1

A method for treating a subject having melanoma with adjuvant therapy, the method comprising:
determining in a sample from the subject that the LY75 promoter is methylated; and then treating the subject with adjuvant therapy so as to treat the melanoma.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the sample is obtained from the skin of the subject or from a melanoma.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the sample is obtained from a biopsy taken from the subject.

### Claim 4 (depends on 1)

The method according to claim 1, further comprising determining tumor ulceration, determining metastatic disease at diagnosis, determining disease stage, and or determining Breslow thickness of the melanoma.

### Claim 5 (depends on 1)

The method according claim 1, wherein the methylation status of the LY75 promoter is determined by polymerase chain reaction-based methylation analysis.

### Claim 6 (depends on 5)

The method according to claim 5 wherein the polymerase chain reaction-based methylation analysis comprises nested primers.

### Claim 7 (depends on 1)

The method according to claim 1, wherein 20% or more of the LY75 promoters in the sample are methylated.